PRELOAD PRELOAD PRELOAD PRELOAD PRELOAD

Media

Company Overview

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.

The company's product portfolio comprises three approved products and multiple clinical and nonclinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan ® (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Investigational product candidates include 6R-BH4 for cardiovascular indications, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU, and GALNS for the treatment of MPS IVA (Morquio A Syndrome).

Company Information

Established: 1997
Headquarters: Novato, California USA
Stock Symbol: NASDAQ: BMRN
Stock Quote: More

2007 Financial Highlights

Total Revenue: $121.6 Million
Net Loss: $15.8 Million
Net Income: $2.6 Million
Employees: 600 worldwide
Clinical Research: Conducted internationally
Manufacturing Operations: Novato, California USA
Products: KUVAN® for PKU, Naglazyme® for MPS VI, Aldurazyme® for MPS I
Commercial Operations: Multinational
Clinical Pipeline: PEG-PAL for PKU, 6R-BH4 for cardiovascular indications
Nonclinical Pipeline: IgA Protease for IgA Nephropathy, GALNS for MPS IVA (Morquio Syndrome), Utrophin Inducer for Duchenne Muscular Dystrophy, BH4 Prodrug for BH4 Applications, GAA for Pompe Disease
Focus: Rare (Orphan) genetic diseases
Proven Expertise: Strong Business Model, Product Development, Manufacturing, Clinical/Regulatory, Global Commercialization
Strategy: Providing rapid access to treatment for patients with serious unmet medical needs, Optimizing powerful biology with demonstrated potential and development clarity, Accelerating approval process, Strategic pipeline development

Products

BioMarin has developed and commercialized three products in ten years, a remarkable accomplishment in the biopharmaceutical industry, and a testament to the company’s passion and dedication to patients with serious unmet medical needs. For complete safety and prescribing information, including a boxed warning for Aldurazyme, please visit www.kuvan.com, www.naglazyme.com and www.aldurazyme.com.